HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Steatohepatitis — Clinical Guidelines

Overview

Steatohepatitis, particularly nonalcoholic steatohepatitis (NASH), is a progressive liver disease characterized by hepatic fat accumulation, inflammation, and potential fibrosis, which can lead to cirrhosis and hepatocellular carcinoma 1 3.

Diagnosis

Key Diagnostic Criteria: Presence of steatosis with inflammation and hepatocyte ballooning on liver biopsy 2.

Recommended Tests: Liver biopsy remains the gold standard for grading steatosis, lobular inflammation, and fibrosis 2.

Noninvasive Tests: Use of noninvasive markers such as FibroMeter, FibroScan (elastography), and blood tests (e.g., ALT, AST, ALP, GGT) to identify high-risk patients 2.

Grading: Histological scoring systems like the NAS (NAFLD Activity Score) and staging systems like the METAVIR or Batts-Ludwig for fibrosis 2.

Management

First-Line Treatments: Lifestyle modifications including weight loss and dietary changes 4.

Weight Loss Medications: Adjunctive use of weight loss medications to achieve significant TBWL (10%) leading to histological improvement 4.

Specific Drug Classes: No specific FDA-approved medications as of 2021, but ongoing research includes vitamin D analogs (e.g., 1,25(OH)2D3) 5, antioxidants (e.g., astaxanthin, vitamin E), and metabolic modulators (e.g., tazuma) 7 9.

Supplements: Preclinical studies suggest potential benefits from vitamin B5, N-acetylcysteine, branched-chain amino acids, and microelements 8 9.

Folic Acid: Pilot studies indicate potential safety and efficacy in improving liver biochemistries in NASH patients 10.

Special Populations

Pregnancy: Limited data; caution advised due to metabolic changes and potential impact on liver function 11.

Elderly: Higher prevalence of comorbidities like obesity and insulin resistance, necessitating tailored management approaches 2.

Comorbidities: Common comorbidities such as obesity, insulin resistance, and type 2 diabetes mellitus influence disease progression and management strategies 2.

Key Recommendations

Utilize Noninvasive Tests to identify patients with NASH at high risk of adverse outcomes, integrating clinical judgment with biomarkers 2 (Evidence: Moderate).

Prioritize Lifestyle Modifications including significant weight loss (7-10% TBWL) as the cornerstone of NASH management 4 (Evidence: Moderate).

Consider Adjunctive Therapies such as weight loss medications and specific supplements based on emerging preclinical evidence, while awaiting definitive clinical trial results 4 8 9 (Evidence: Weak).

Monitor and Address Comorbidities like obesity and diabetes to mitigate NASH progression 2 (Evidence: Moderate).

Evaluate Folic Acid Supplementation in NASH patients for potential biochemical improvements, though further clinical validation is needed 10 (Evidence: Weak).

References

1 Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver international : official journal of the International Association for the Study of the Liver 2021. link 2 Younossi ZM, Noureddin M, Bernstein D, Kwo P, Russo M, Shiffman ML et al.. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations. The American journal of gastroenterology 2021. link 3 Alkhouri N, Tincopa M, Loomba R, Harrison SA. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?. Hepatology communications 2021. link 4 Do A, Kuszewski EJ, Langberg KA, Mehal WZ. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology (Baltimore, Md.) 2019. link 5 Ma L, Ishigami M, Honda T, Yokoyama S, Yamamoto K, Ishizu Y et al.. Antifibrotic Effects of 1,25(OH). Digestive diseases and sciences 2019. link 6 Li C, Xu Y. Letter to the Editor: Bioinformatics Analysis in Mice with Diet-Induced Nonalcoholic Steatohepatitis Treated with Astaxanthin and Vitamin E. International journal of molecular sciences 2017. link 7 Friedman SL, Lee YA. Devilish Effects of Taz in Nonalcoholic Steatohepatitis. Cell metabolism 2016. link 8 Machado MV, Kruger L, Jewell ML, Michelotti GA, Pereira Tde A, Xie G et al.. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model. Digestive diseases and sciences 2016. link 9 Tanaka H, Fukahori S, Baba S, Ueno T, Sivakumar R, Yagi M et al.. Branched-Chain Amino Acid-Rich Supplements Containing Microelements Have Antioxidant Effects on Nonalcoholic Steatohepatitis in Mice. JPEN. Journal of parenteral and enteral nutrition 2016. link 10 Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD. Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver international : official journal of the International Association for the Study of the Liver 2007. link 11 Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989. link91513-8)

Steatohepatitis